Radequinil

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABA_A receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

Radequinil

Clinical data
ATC code	None
Identifiers
IUPAC name 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
CAS Number	219846-31-8
PubChem CID	22714308
ChemSpider	11584471
UNII	2G222T03EY
CompTox Dashboard (EPA)	DTXSID60944577
Chemical and physical data
Formula	C18H14N4O3
Molar mass	334.335 g·mol^−1
3D model (JSmol)	Interactive image
SMILES COc1cccc(c1)c3nccc2NC(=O)\C(=C/c23)c4nc(C)on4
InChI InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23) Key:JQOFKKWHXGQABB-UHFFFAOYSA-N

See also

• GABA_A receptor negative allosteric modulator
• GABA_A receptor § Ligands

References

1. Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23. doi:10.2174/1876523800801010019.
2. Pogacić V, Herrling P (2007). "List of drugs in development for neurodegenerative diseases. Update June 2007". Neuro-Degenerative Diseases. 4 (6): 443–86. doi:10.1159/000107705. PMID 17934328.